How should varenicline (Chantix) be prescribed for smoking cessation in an adult patient, including dosing schedule, contraindications, monitoring, and alternative options?

Varenicline (Chantix) for Smoking Cessation

Varenicline is a preferred first-line medication for smoking cessation, equally effective as combination nicotine replacement therapy (NRT), and should be prescribed using a standard titration schedule starting 1-2 weeks before the quit date, with a minimum 12-week treatment course. 12

Dosing Schedule

Standard Titration Protocol:

• Days 1-3: 0.5 mg orally once daily
• Days 4-7: 0.5 mg orally twice daily
• Week 2 through Week 12: 1 mg orally twice daily (if tolerated)

122

Key Prescribing Details:

• Begin dosing 1-2 weeks before the target quit date 12
• Take after eating with a full glass of water 22
• Minimum treatment duration: 12 weeks 11
• Extended therapy: An additional 12 weeks (total 24 weeks) is recommended for patients who successfully quit to increase long-term abstinence 12

Alternative Dosing Approaches

Gradual Quit Approach (for patients unable/unwilling to quit abruptly):

• Start varenicline and reduce smoking by 50% within first 4 weeks
• Reduce by another 50% in next 4 weeks
• Achieve complete abstinence by week 12
• Continue treatment for additional 12 weeks (total 24 weeks) 22

Flexible Dosing: Evidence suggests 0.5 mg twice daily may be equally effective as 1 mg twice daily (46.4% vs 46.5% abstinence at 1 year), with potentially fewer side effects 3. Consider dose reduction if patients cannot tolerate standard dosing 12.

Contraindications and Critical Warnings

Absolute Contraindication:

• Brain metastases (due to seizure risk) 111
• Known serious hypersensitivity or skin reactions to varenicline 2

Monitor Closely (Not Contraindications): The 2016 EAGLES trial definitively showed that neuropsychiatric adverse events with varenicline were not significantly increased compared to nicotine patches or placebo in patients with or without psychiatric disorders 11. However, prudent monitoring remains warranted:

• Neuropsychiatric symptoms: Monitor for development or worsening of depression, suicidal ideation/behavior, hostility, agitation 112
• Discontinue immediately if serious neuropsychiatric symptoms occur 11
• Note: Historic concerns about psychiatric risks have been largely disproven, but provider hesitancy persists, particularly for schizophrenia 4

Monitoring Protocol

Follow-up Schedule:

• Within 2-3 weeks after starting pharmacotherapy (in-person or phone) 111
• At 12 weeks (end of initial treatment course) 11
• Additional periodic follow-up at minimum 12-week intervals during extended therapy 1

What to Monitor:

• Smoking status and abstinence
• Medication adherence
• Adverse effects (especially nausea, neuropsychiatric symptoms)
• Nicotine withdrawal symptoms (peak at 1-2 weeks, then subside) 11

Common Side Effects and Management

Most Common Adverse Event:

• Nausea: Occurs in 30-40% of patients 56
  • Generally mild to moderate
  • Diminishes over time
  • Attributable discontinuation rate: 0.6-7.6% 5
  • Critical for cancer patients: May need proactive management, especially during chemotherapy 11

Other Common Effects:

• Insomnia, abnormal dreams, headache, fatigue 76
• Serious adverse events are rare 11

Special Populations

Severe Renal Impairment (CrCl <30 mL/min):

• Start: 0.5 mg once daily
• Maximum: 0.5 mg twice daily 22

End-Stage Renal Disease (hemodialysis):

• Maximum: 0.5 mg once daily 22

Mild-Moderate Renal Impairment: No dose adjustment needed 22

Hepatic Impairment: No dose adjustment needed 22

Elderly: No dose adjustment, but monitor renal function 22

Cardiovascular Disease: Safe to use; initial concerns about cardiovascular adverse events have been disproven 78

Alternative Options

If Varenicline Fails or Is Not Tolerated:

1. Combination NRT (equally preferred first-line option):

   • 21 mg nicotine patch + short-acting NRT (gum/lozenge/inhaler/nasal spray)
   • Consider increasing patch to 35-42 mg if 21 mg ineffective 11

2. Bupropion ± NRT (second-line):

   • Days 1-3: 150 mg once daily
   • Day 4 onward: 150 mg twice daily (max 300 mg/day)
   • Duration: 7-12 weeks 11
   • Contraindicated: Seizure disorders, stroke, brain metastases, MAO inhibitor use, tamoxifen use, closed-angle glaucoma 1

3. Switch therapies if reduction efforts stall or abstinence seems unlikely 11

Critical Practice Points

Behavioral Support is Essential:

• Combining varenicline with counseling is superior to either alone 99
• Minimum 4 sessions of individual/group therapy over 12 weeks preferred 1
• Provide educational materials and motivational support 22

Managing Treatment Failure:

• Encourage continued therapy through brief slips 11
• Patients may quit later after withdrawal symptoms subside 1
• For relapse: Resume initial therapy or switch to alternative option 1
• Intensify behavioral therapy with each treatment line 1

Common Pitfall: The benefits of immediate smoking cessation substantially outweigh the minimal risks of varenicline, even in patients with psychiatric comorbidities 11. Don't withhold effective treatment due to outdated safety concerns.